{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T13:38:08Z","timestamp":1761745088731,"version":"3.37.3"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,12,30]],"date-time":"2019-12-30T00:00:00Z","timestamp":1577664000000},"content-version":"vor","delay-in-days":29,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["R01 AG054130"],"award-info":[{"award-number":["R01 AG054130"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000009","name":"Foundation for the National Institutes of Health","doi-asserted-by":"publisher","award":["UL1TR000117"],"award-info":[{"award-number":["UL1TR000117"]}],"id":[{"id":"10.13039\/100000009","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>The course of Alzheimer\u2019s disease (AD) includes a 10\u201320-year preclinical period with progressive accumulation of amyloid \u03b2 (A\u03b2) plaques and neurofibrillary tangles in the absence of symptomatic cognitive or functional decline. The duration of this preclinical stage in part depends on the rate of pathologic progression, which is offset by compensatory mechanisms, referred to as cognitive reserve (CR). Comorbid medical conditions, psychosocial stressors, and inappropriate medication use may lower CR, hastening the onset of symptomatic AD. Here, we describe a randomized controlled trial (RCT) designed to test the efficacy of a medication therapy management (MTM) intervention to reduce inappropriate medication use, bolster cognitive reserve, and ultimately delay symptomatic AD.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods\/design<\/jats:title>\n                <jats:p>Our study aims to enroll 90 non-demented community-dwelling adults \u2265\u200965\u2009years of age. Participants will undergo positron emission tomography (PET) scans, measuring A\u03b2 levels using standardized uptake value ratios (SUVr). Participants will be randomly assigned to MTM intervention or control, stratified by A\u03b2 levels, and followed for 12\u2009months via in-person and telephone visits. Outcomes of interest include: (1) medication appropriateness (measured with the Medication Appropriateness Index (MAI)); (2) scores from Trail Making Test B (TMTB), Montreal Cognitive Assessment (MoCA), and California Verbal Learning Test (CVLT); (3) perceived health status (measured with the SF-36). We will also evaluate pre- to post-intervention change in: (1) use of inappropriate medications as measured by MAI; 2) CR Change Score (CRCS), defined as the difference in scopolamine-challenged vs unchallenged cognitive scores at baseline and follow-up. Baseline A\u03b2 SUVr will be used to examine the relative impact of preclinical AD (pAD) pathology on CRCS, as well as the interplay of amyloid burden with inappropriate medication use.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Discussion<\/jats:title>\n                <jats:p>This manuscript describes the protocol of INCREASE (\u201cINtervention for Cognitive Reserve Enhancement in delaying the onset of Alzheimer\u2019s Symptomatic Expression\u201d): a randomized controlled trial that investigates the impact of deprescribing inappropriate medications and optimizing medication regimens on potentially delaying the onset of symptomatic AD and AD-related dementias.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration<\/jats:title>\n                <jats:p>ClinicalTrials.gov, <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02849639\">NCT02849639<\/jats:ext-link>. Registered on 29 July 2016.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13063-019-3993-0","type":"journal-article","created":{"date-parts":[[2019,12,30]],"date-time":"2019-12-30T21:02:21Z","timestamp":1577739741000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["INtervention for Cognitive Reserve Enhancement in delaying the onset of Alzheimer\u2019s Symptomatic Expression (INCREASE), a randomized controlled trial: rationale, study design, and protocol"],"prefix":"10.1186","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3648-8197","authenticated-orcid":false,"given":"Daniela C.","family":"Moga","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brooke F.","family":"Beech","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erin L.","family":"Abner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frederick A.","family":"Schmitt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Riham H.","family":"El Khouli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashley I.","family":"Martinez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lynne","family":"Eckmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Huffmyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosmy","family":"George","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregory A.","family":"Jicha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,12,30]]},"reference":[{"key":"3993_CR1","volume-title":"Alzheimer\u2019s facts and figures","author":"Alzheimer's Association","year":"2019","unstructured":"Alzheimer's Association: Alzheimer\u2019s facts and figures. 2019. https:\/\/www.alz.org\/media\/documents\/alzheimers-facts-and-figures-2019-r.pdf. Accessed 1 Oct 2019."},{"issue":"4","key":"3993_CR2","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1097\/00002093-200110000-00002","volume":"15","author":"LE Hebert","year":"2001","unstructured":"Hebert LE, et al. Annual incidence of Alzheimer disease in the United States projected to the years 2000 through 2050. Alzheimer Dis Assoc Disord. 2001;15(4):169\u201373.","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"3993_CR3","unstructured":"Changing the trajectory of Alzheimer\u2019s disease: How a treatment by 2025 saves lives and dollars. 2015. https:\/\/www.alz.org\/media\/documents\/changing-the-trajectory-r.pdf. Accessed 1 Oct 2019."},{"issue":"3","key":"3993_CR4","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.jalz.2011.03.003","volume":"7","author":"RA Sperling","year":"2011","unstructured":"Sperling RA, et al. Toward defining the preclinical stages of Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimers Dement. 2011;7(3):280\u201392.","journal-title":"Alzheimers Dement"},{"issue":"11","key":"3993_CR5","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1016\/S1474-4422(12)70191-6","volume":"11","author":"Y Stern","year":"2012","unstructured":"Stern Y. Cognitive reserve in ageing and Alzheimer\u2019s disease. Lancet Neurol. 2012;11(11):1006\u201312.","journal-title":"Lancet Neurol"},{"issue":"8","key":"3993_CR6","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1093\/gerona\/glv013","volume":"70","author":"CJ Charlesworth","year":"2015","unstructured":"Charlesworth CJ, et al. Polypharmacy among adults aged 65 years and older in the United States: 1988-2010. J Gerontol A Biol Sci Med Sci. 2015;70(8):989\u201395.","journal-title":"J Gerontol A Biol Sci Med Sci"},{"issue":"10","key":"3993_CR7","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1001\/archneurol.2009.201","volume":"66","author":"LE Middleton","year":"2009","unstructured":"Middleton LE, Yaffe K. Promising strategies for the prevention of dementia. Arch Neurol. 2009;66(10):1210\u20135.","journal-title":"Arch Neurol"},{"key":"3993_CR8","doi-asserted-by":"publisher","unstructured":"Angevaren M, Aufdemkampe G, Verhaar HJJ, Aleman A, Vanhees L. Physical activity and enhanced fitness to improve cognitive function in older people without known cognitive impairment. Cochrane Database Syst Rev. 2008;(3):CD005381. https:\/\/doi.org\/10.1002\/14651858.CD005381.pub3","DOI":"10.1002\/14651858.CD005381.pub3"},{"issue":"Suppl 1","key":"3993_CR9","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.neurobiolaging.2005.09.009","volume":"26","author":"AF Kramer","year":"2005","unstructured":"Kramer AF, et al. Fitness, aging and neurocognitive function. Neurobiol Aging. 2005;26(Suppl 1):124\u20137.","journal-title":"Neurobiol Aging"},{"key":"3993_CR10","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/0001-6918(89)90012-7","volume":"71","author":"M Fabiani","year":"1989","unstructured":"Fabiani M, Buckley J, Gratton G, Coles MGH, Donkin E. The training of complex task performance. Acta Psychol. 1989;71:259\u201399.","journal-title":"Acta Psychol"},{"issue":"3","key":"3993_CR11","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1177\/001872089403600301","volume":"36","author":"D Gopher","year":"1994","unstructured":"Gopher D, Well M, Bareket T. Transfer of skill from a computer game trainer to flight. Hum Factors. 1994;36(3):387\u2013405.","journal-title":"Hum Factors"},{"issue":"6985","key":"3993_CR12","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1136\/bmj.310.6985.951","volume":"310","author":"M Orrell","year":"1995","unstructured":"Orrell M, Sahakian B. Education and dementia. BMJ. 1995;310(6985):951\u20132.","journal-title":"BMJ"},{"issue":"3","key":"3993_CR13","first-page":"140","volume":"5","author":"M Fotuhi","year":"2009","unstructured":"Fotuhi M, Mohassel P, Yaffe K. Fish consumption, long-chain omega-3 fatty acids and risk of cognitive decline or Alzheimer disease: a complex association. Nat Clin Pract Neurol. 2009;5(3):140\u201352.","journal-title":"Nat Clin Pract Neurol"},{"issue":"2","key":"3993_CR14","first-page":"132","volume":"11","author":"S Gillette Guyonnet","year":"2007","unstructured":"Gillette Guyonnet S, et al. IANA task force on nutrition and cognitive decline with aging. J Nutr Health Aging. 2007;11(2):132\u201352.","journal-title":"J Nutr Health Aging"},{"issue":"22","key":"3993_CR15","doi-asserted-by":"publisher","first-page":"2462","DOI":"10.1001\/archinte.166.22.2462","volume":"166","author":"JH Kang","year":"2006","unstructured":"Kang JH, et al. A randomized trial of vitamin E supplementation and cognitive function in women. Arch Intern Med. 2006;166(22):2462\u20138.","journal-title":"Arch Intern Med"},{"issue":"9","key":"3993_CR16","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1212\/01.WNL.0000142969.19465.8F","volume":"63","author":"K Yaffe","year":"2004","unstructured":"Yaffe K, et al. Impact of antioxidants, zinc, and copper on cognition in the elderly: a randomized, controlled trial. Neurology. 2004;63(9):1705\u20137.","journal-title":"Neurology"},{"issue":"5","key":"3993_CR17","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/alzrt213","volume":"5","author":"KL Moulder","year":"2013","unstructured":"Moulder KL, et al. Dominantly Inherited Alzheimer Network: facilitating research and clinical trials. Alzheimers Res Ther. 2013;5(5):48.","journal-title":"Alzheimers Res Ther"},{"issue":"228","key":"3993_CR18","doi-asserted-by":"publisher","first-page":"228fs13","DOI":"10.1126\/scitranslmed.3007941","volume":"6","author":"RA Sperling","year":"2014","unstructured":"Sperling RA, et al. The A4 study: stopping AD before symptoms begin? Sci Transl Med. 2014;6(228):228fs13.","journal-title":"Sci Transl Med"},{"issue":"1","key":"3993_CR19","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1097\/WAD.0b013e31819d6ec9","volume":"24","author":"DT Lau","year":"2010","unstructured":"Lau DT, et al. Polypharmacy and potentially inappropriate medication use among community-dwelling elders with dementia. Alzheimer Dis Assoc Disord. 2010;24(1):56\u201363.","journal-title":"Alzheimer Dis Assoc Disord"},{"issue":"4","key":"3993_CR20","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1111\/jgs.15767","volume":"67","author":"By the American Geriatrics Society Beers Criteria Update Expert Panel","year":"2019","unstructured":"By the American Geriatrics Society Beers Criteria Update Expert Panel. American Geriatrics Society 2019 updated AGS Beers criteria(R) for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2019;67(4):674\u201394.","journal-title":"J Am Geriatr Soc"},{"issue":"12","key":"3993_CR21","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1111\/jgs.13701","volume":"63","author":"Michael A. Steinman","year":"2015","unstructured":"Steinman MA, et al. How to use the American Geriatrics Society 2015 Beers criteria-a guide for patients, clinicians, health systems, and payors. J Am Geriatr Soc. 2015;63(12):e1-e7. https:\/\/doi.org\/10.1111\/jgs.13701. Epub 2015 Oct 8.","journal-title":"Journal of the American Geriatrics Society"},{"issue":"2","key":"3993_CR22","first-page":"168","volume":"57","author":"B Farrell","year":"2011","unstructured":"Farrell B, Szeto W, Shamji S. Drug-related problems in the frail elderly. Can Fam Physician. 2011;57(2):168\u20139.","journal-title":"Can Fam Physician"},{"issue":"3","key":"3993_CR23","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1111\/jgs.13320","volume":"63","author":"AJ Davidoff","year":"2015","unstructured":"Davidoff AJ, et al. Prevalence of potentially inappropriate medication use in older adults using the 2012 Beers criteria. J Am Geriatr Soc. 2015;63(3):486\u2013500.","journal-title":"J Am Geriatr Soc"},{"issue":"1","key":"3993_CR24","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s13195-017-0263-9","volume":"9","author":"DC Moga","year":"2017","unstructured":"Moga DC, et al. Optimizing medication appropriateness in older adults: a randomized clinical interventional trial to decrease anticholinergic burden. Alzheimers Res Ther. 2017;9(1):36.","journal-title":"Alzheimers Res Ther"},{"issue":"4","key":"3993_CR25","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/j.amjopharm.2007.12.009","volume":"5","author":"MA Steinman","year":"2007","unstructured":"Steinman MA. Polypharmacy and the balance of medication benefits and risks. Am J Geriatr Pharmacother. 2007;5(4):314\u20136.","journal-title":"Am J Geriatr Pharmacother"},{"issue":"10","key":"3993_CR26","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1016\/0895-4356(92)90144-C","volume":"45","author":"JT Hanlon","year":"1992","unstructured":"Hanlon JT, et al. A method for assessing drug therapy appropriateness. J Clin Epidemiol. 1992;45(10):1045\u201351.","journal-title":"J Clin Epidemiol"},{"key":"3993_CR27","doi-asserted-by":"publisher","first-page":"103208","DOI":"10.1016\/j.jbi.2019.103208","volume":"95","author":"PA Harris","year":"2019","unstructured":"Harris PA, et al. The REDCap consortium: Building an international community of software platform partners. J Biomed Inform. 2019;95:103208.","journal-title":"J Biomed Inform"},{"issue":"2","key":"3993_CR28","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","volume":"42","author":"PA Harris","year":"2009","unstructured":"Harris PA, et al. Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;42(2):377\u201381.","journal-title":"J Biomed Inform"},{"issue":"2","key":"3993_CR29","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/j.jalz.2014.01.009","volume":"10","author":"PJ Snyder","year":"2014","unstructured":"Snyder PJ, et al. Microdosing of scopolamine as a \u201ccognitive stress test\u201d: rationale and test of a very low dose in an at-risk cohort of older adults. Alzheimers Dement. 2014;10(2):262\u20137.","journal-title":"Alzheimers Dement"},{"issue":"3","key":"3993_CR30","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1001\/jama.2010.2008","volume":"305","author":"CM Clark","year":"2011","unstructured":"Clark CM, et al. Use of florbetapir-PET for imaging beta-amyloid pathology. JAMA. 2011;305(3):275\u201383.","journal-title":"JAMA"},{"issue":"11","key":"3993_CR31","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1001\/archneurol.2011.150","volume":"68","author":"AS Fleisher","year":"2011","unstructured":"Fleisher AS, et al. Using positron emission tomography and florbetapir F18 to image cortical amyloid in patients with mild cognitive impairment or dementia due to Alzheimer disease. Arch Neurol. 2011;68(11):1404\u201311.","journal-title":"Arch Neurol"},{"issue":"3","key":"3993_CR32","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1016\/j.neuron.2014.10.038","volume":"84","author":"R Sperling","year":"2014","unstructured":"Sperling R, Mormino E, Johnson K. The evolution of preclinical Alzheimer\u2019s disease: implications for prevention trials. Neuron. 2014;84(3):608\u201322.","journal-title":"Neuron"},{"issue":"16","key":"3993_CR33","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1212\/WNL.0b013e3182661f74","volume":"79","author":"PM Doraiswamy","year":"2012","unstructured":"Doraiswamy PM, et al. Amyloid-beta assessed by florbetapir F 18 PET and 18-month cognitive decline: a multicenter study. Neurology. 2012;79(16):1636\u201344.","journal-title":"Neurology"},{"issue":"4","key":"3993_CR34","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/S0002-9343(97)89519-8","volume":"100","author":"JT Hanlon","year":"1996","unstructured":"Hanlon JT, et al. A randomized, controlled trial of a clinical pharmacist intervention to improve inappropriate prescribing in elderly outpatients with polypharmacy. Am J Med. 1996;100(4):428\u201337.","journal-title":"Am J Med"},{"key":"3993_CR35","doi-asserted-by":"publisher","unstructured":"By the American Geriatrics Society Beers Criteria Update Expert Panel. American Geriatrics Society 2015 updated Beers criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2015;63(11):2227\u201346. https:\/\/doi.org\/10.1111\/jgs.13702. Epub 2015 Oct 8.","DOI":"10.1111\/jgs.13702"},{"issue":"12","key":"3993_CR36","doi-asserted-by":"publisher","first-page":"e8","DOI":"10.1111\/jgs.13807","volume":"63","author":"Joseph T. Hanlon","year":"2015","unstructured":"Hanlon JT, Semla TP, Schmader KE. Alternative medications for medications in the use of high-risk medications in the elderly and potentially harmful drug-disease interactions in the elderly quality measures. J Am Geriatr Soc. 2015;63(12):e8-e18. https:\/\/doi.org\/10.1111\/jgs.13807. Epub 2015 Oct 8.","journal-title":"Journal of the American Geriatrics Society"},{"key":"3993_CR37","unstructured":"Crossing the quality chasm: a new health system for the 21st century. Washington (DC); 2001. http:\/\/www.nationalacademies.org\/hmd\/~\/media\/Files\/Report%20Files\/2001\/Crossing-the-Quality-Chasm\/Quality%20Chasm%202001%20%20report%20brief.pdf. Accessed 1 Oct 2019."},{"issue":"3","key":"3993_CR38","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1016\/j.pec.2014.08.021","volume":"97","author":"JL Kuntz","year":"2014","unstructured":"Kuntz JL, et al. Patient-centered interventions to improve medication management and adherence: a qualitative review of research findings. Patient Educ Couns. 2014;97(3):310\u201326.","journal-title":"Patient Educ Couns"},{"issue":"4","key":"3993_CR39","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1002\/nur.10044","volume":"25","author":"DR Lauver","year":"2002","unstructured":"Lauver DR, et al. Patient-centered interventions. Res Nurs Health. 2002;25(4):246\u201355.","journal-title":"Res Nurs Health"},{"issue":"2","key":"3993_CR40","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/S0887-6177(03)00039-8","volume":"19","author":"TN Tombaugh","year":"2004","unstructured":"Tombaugh TN. Trail Making Test A and B: normative data stratified by age and education. Arch Clin Neuropsychol. 2004;19(2):203\u201314.","journal-title":"Arch Clin Neuropsychol"},{"issue":"2","key":"3993_CR41","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1097\/WAD.0b013e318191c7dd","volume":"23","author":"S Weintraub","year":"2009","unstructured":"Weintraub S, et al. The Alzheimer\u2019s Disease Centers\u2019 Uniform Data Set (UDS): the neuropsychologic test battery. Alzheimer Dis Assoc Disord. 2009;23(2):91\u2013101.","journal-title":"Alzheimer Dis Assoc Disord"},{"issue":"4","key":"3993_CR42","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1111\/j.1532-5415.2005.53221.x","volume":"53","author":"ZS Nasreddine","year":"2005","unstructured":"Nasreddine ZS, et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005;53(4):695\u20139.","journal-title":"J Am Geriatr Soc"},{"issue":"10","key":"3993_CR43","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1212\/01.wnl.0000413072.54070.a3","volume":"78","author":"ZS Nasreddine","year":"2012","unstructured":"Nasreddine ZS, Phillips N, Chertkow H. Normative data for the Montreal Cognitive Assessment (MoCA) in a population-based sample. Neurology. 2012;78(10):765\u20136 author reply 766.","journal-title":"Neurology"},{"issue":"5","key":"3993_CR44","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/j.acn.2006.06.002","volume":"21","author":"SP Woods","year":"2006","unstructured":"Woods SP, et al. The California Verbal Learning Test--second edition: test-retest reliability, practice effects, and reliable change indices for the standard and alternate forms. Arch Clin Neuropsychol. 2006;21(5):413\u201320.","journal-title":"Arch Clin Neuropsychol"},{"issue":"6","key":"3993_CR45","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1159\/000340006","volume":"33","author":"AS Costa","year":"2012","unstructured":"Costa AS, et al. Alternate-form reliability of the Montreal cognitive assessment screening test in a clinical setting. Dement Geriatr Cogn Disord. 2012;33(6):379\u201384.","journal-title":"Dement Geriatr Cogn Disord"},{"issue":"6","key":"3993_CR46","doi-asserted-by":"publisher","first-page":"724","DOI":"10.2174\/156720512801322591","volume":"9","author":"FA Schmitt","year":"2012","unstructured":"Schmitt FA, et al. University of Kentucky Sanders-Brown healthy brain aging volunteers: donor characteristics, procedures and neuropathology. Curr Alzheimer Res. 2012;9(6):724\u201333.","journal-title":"Curr Alzheimer Res"},{"issue":"4","key":"3993_CR47","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1097\/JGP.0b013e31802dd354","volume":"15","author":"KA Bottiggi","year":"2007","unstructured":"Bottiggi KA, et al. Concomitant use of medications with anticholinergic properties and acetylcholinesterase inhibitors: impact on cognitive and physical functioning in Alzheimer disease. Am J Geriatr Psychiatry. 2007;15(4):357\u20139.","journal-title":"Am J Geriatr Psychiatry"},{"issue":"1","key":"3993_CR48","doi-asserted-by":"publisher","first-page":"253","DOI":"10.3233\/JAD-2010-1237","volume":"19","author":"GA Jicha","year":"2010","unstructured":"Jicha GA, Carr SA. Conceptual evolution in Alzheimer\u2019s disease: implications for understanding the clinical phenotype of progressive neurodegenerative disease. J Alzheimers Dis. 2010;19(1):253\u201372.","journal-title":"J Alzheimers Dis"},{"issue":"5","key":"3993_CR49","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1097\/00005650-198105000-00001","volume":"19","author":"AL Stewart","year":"1981","unstructured":"Stewart AL, Ware JE Jr, Brook RH. Advances in the measurement of functional status: construction of aggregate indexes. Med Care. 1981;19(5):473\u201388.","journal-title":"Med Care"},{"issue":"12","key":"3993_CR50","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.2105\/AJPH.65.12.1304","volume":"65","author":"BS Gilson","year":"1975","unstructured":"Gilson BS, et al. The sickness impact profile. Development of an outcome measure of health care. Am J Public Health. 1975;65(12):1304\u201310.","journal-title":"Am J Public Health"},{"issue":"7","key":"3993_CR51","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1111\/j.1532-5415.1991.tb03623.x","volume":"39","author":"M Weinberger","year":"1991","unstructured":"Weinberger M, et al. An evaluation of a brief health status measure in elderly veterans. J Am Geriatr Soc. 1991;39(7):691\u20134.","journal-title":"J Am Geriatr Soc"},{"issue":"11","key":"3993_CR52","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1007\/s40266-013-0118-4","volume":"30","author":"JT Hanlon","year":"2013","unstructured":"Hanlon JT, Schmader KE. The medication appropriateness index at 20: where it started, where it has been, and where it may be going. Drugs Aging. 2013;30(11):893\u2013900.","journal-title":"Drugs Aging"},{"issue":"11","key":"3993_CR53","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1097\/01.JGP.0000224619.87681.71","volume":"14","author":"KA Bottiggi","year":"2006","unstructured":"Bottiggi KA, et al. Long-term cognitive impact of anticholinergic medications in older adults. Am J Geriatr Psychiatry. 2006;14(11):980\u20134.","journal-title":"Am J Geriatr Psychiatry"},{"issue":"5","key":"3993_CR54","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1002\/hup.942","volume":"23","author":"A Fredrickson","year":"2008","unstructured":"Fredrickson A, et al. The use of effect sizes to characterize the nature of cognitive change in psychopharmacological studies: an example with scopolamine. Hum Psychopharmacol. 2008;23(5):425\u201336.","journal-title":"Hum Psychopharmacol"},{"key":"3993_CR55","doi-asserted-by":"publisher","unstructured":"Stern Y, et al. Whitepaper: Defining and investigating cognitive reserve, brain reserve, and brain maintenance. Alzheimers Dement. 2018. https:\/\/doi.org\/10.1016\/j.jalz.2018.07.219.","DOI":"10.1016\/j.jalz.2018.07.219"}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-019-3993-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13063-019-3993-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-019-3993-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,29]],"date-time":"2020-12-29T00:26:20Z","timestamp":1609201580000},"score":1,"resource":{"primary":{"URL":"https:\/\/trialsjournal.biomedcentral.com\/articles\/10.1186\/s13063-019-3993-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":55,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["3993"],"URL":"https:\/\/doi.org\/10.1186\/s13063-019-3993-0","relation":{},"ISSN":["1745-6215"],"issn-type":[{"type":"electronic","value":"1745-6215"}],"subject":[],"published":{"date-parts":[[2019,12]]},"assertion":[{"value":"6 October 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 December 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 December 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was approved by the Institutional Review Board at University of Kentucky (IRB #43239) and all participants provide signed informed consent for participation.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"806"}}